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ABSTRACT
Antimicrobial resistance has been an issue since the introduction into clinical use of the ﬁrst agents in the
1940s. Although the discovery and development of new classes of antimicrobials through the 1960s
presented an array of treatment options, these options for some serious and life-threatening infectious
diseases may now be more limited. This paper examines the history of antimicrobial development,
showing how the challenges in discovering new classes of drugs have been with us for the last 40 years.
The present state of antimicrobial discovery and development is shaped by these challenges as well as
by the economic realities of the pharmaceutical industry. This paper also discusses some of the
regulatory considerations in antimicrobial drug development, and presents some potential solutions to
the challenges inherent in antimicrobial drug development, including steps taken by the US Food and
Drug Administration to streamline the drug review process for antimicrobial agents while maintaining
the standards necessary to protect and promote the health of the public.
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INTRODUCTION
The introduction of antimicrobial agents into
general clinical use represents one of the land-
mark medical advances of modern medicine. In
the last half of the 20th century, a number of new
antimicrobials came into clinical use, presenting
clinicians with an array of choices when treating
many types of infectious diseases. However, the
issue of antimicrobial resistance that has been a
concern ever since the beginning of the antimi-
crobial era, has taken on more importance
recently. Clinicians are witnessing increasing
rates of in vitro resistance among previously
susceptible organisms and the emergence of
intrinsically resistant organisms as pathogens in
immunocompromised hosts. The spread of resis-
tance has in turn limited the treatment options for
some serious and life-threatening diseases. To
curtail the development and spread of antimicro-
bial resistance will require both the preservation
of current antimicrobials through their appropri-
ate use, as well as the discovery and development
of new agents. While there is a need for new
agents, some large pharmaceutical companies
have decided to exit the area of antimicro-
bial development, especially antibacterial drug
development [1]. This paper will examine the
history of antimicrobial drug development, how it
has inﬂuenced the present situation, where
we stand today, and address some of the
potential solutions for spurring future antimi-
crobial development, including the response from
regulatory agencies such as the US Food and
Drug Administration (FDA).
THE PAST
The earliest uses of antimicrobials constituted a
dramatic impact in altering mortality in serious
and life-threatening bacterial diseases compared
with the absence of therapy in the pre-antibiotic
era. The use of subcutaneous sulfanilamide low-
ered the mortality rate of acute meningococcal
meningitis from 70–90% in the pre-antibiotic era
to approximately 10% [2]. It did not require large
studies or many patients to conﬁrm the beneﬁts of
antimicrobials in these serious illnesses. Based
upon these impressive results in the treatment of
severe and life-threatening diseases, clinicians
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expanded the use of antimicrobials to less severe
illnesses. This extrapolation was based upon the
premise that antimicrobials affect the growth of
micro-organisms and therefore should be beneﬁ-
cial in diseases where bacteria are implicated as
the causative pathogens. This premise, however,
did not take into account the self-resolving nature
of many of these illnesses. Data from placebo-
controlled trials to determine the magnitude of
the clinical treatment effect of antimicrobials in
many of these illnesses was, and still remains,
lacking. As will be shown, this has important
implications for the future study of antimicrobials
in some of these diseases that are largely self-
resolving.
The past uses of antimicrobials also demon-
strated issues associated with the safety of these
drugs. In fact, safety issues associated with
antimicrobials have changed the face of public
health. The deaths associated with use of Elixir of
Sulfanilamide resulted in the passage of the Food,
Drug and Cosmetic (FD&C) Act in 1938 [3]. The
adverse effects associated with administration of
thalidomide, a drug used to treat manifestations
of leprosy, resulted in an amendment to the
FD&C Act in 1962 which required drug sponsors
to demonstrate the efﬁcacy of a drug product in
the disease under study. Prior to that time, a drug
sponsor had to show only that a drug was safe in
order to receive an approval for marketing. This
amendment followed from the recognition that
the risk of adverse events associated with drug
usage should be balanced by the beneﬁts achieved
by use of the drug.
In the 30 years following the introduction of
sulfonamides and penicillin, scientists discovered
and developed a wide range of antimicrobials to
treat bacterial diseases, presenting clinicians with
a number of treatment options for most infectious
diseases. The method of discovery of new agents
was largely based on the methods of German and
Swiss scientists from the late 19th century for
evaluating naturally occurring compounds. Many
new antimicrobials were discovered surrepti-
tiously and by observation, such as the discovery
of the original cephalosporin C-producing organ-
ism in sewer water [4]. Many other antimicrobials
were developed by chemical modiﬁcation of
existing agents.
The discovery of new classes of antibacterial
drugs, deﬁned here as drugs with a completely
novel mechanism of action, slowed in the late
1960s. The last novel class of antibacterial prior
to the year 2000 was described in 1968 (Table 1).
The majority of antimicrobials introduced since
that time have been chemical modiﬁcations of
previously discovered classes of drugs. This is
testament to the challenges inherent in the
discovery of new agents. It is also important to
note that the majority of antibacterials were
introduced prior to the 1962 efﬁcacy require-
ment of the FD&C Act.
In spite of a lack of new classes of agents, drug
developers continued to introduce new agents
within existing classes. Some of these agents had
efﬁcacy against diseases caused by pathogens that
were resistant to previous ‘generations’ of the
same class. In addition, some of the drugs
demonstrated improved efﬁcacy in certain dis-
eases compared with previous drugs. For
instance, third generation cephalosporins are
effective in diseases caused by Gram-negative
organisms and in diseases, such as acute bacterial
meningitis, where ﬁrst-generation cephalosporins
are less effective. Other agents had similar efﬁ-
cacy but manifested a different safety proﬁle or a
more convenient dosing schedule. Other agents
introduced during this time represented minor
advances over previous agents within the class
but did present clinicians with an expanded range
of treatment options.
The absence of a variety of new drug classes
since the 1960s is evident when one examines the
history of the FDA approval of antibacterial
agents (Fig. 1). From 1980 to 1989, the FDA
Table 1. History of antibacterial drug introductions and
approval
Year
introduced Class of drug
1935 Sulfonamides
Food Drug and Cosmetics Act 1938 ﬁ
1941 b-lactams (Penicillin)
1944 Aminoglycosides
1949 Chloramphenicol
1950 Tetracyclines
1952 Macrolides ⁄Lincosamides ⁄ Streptogramins
1956 Glycopeptides
1957 Rifamycins
1959 Nitromidiazoles
1962 Quinolones
Kefauver-Harris Amendments 1962 ﬁ
1968 Trimethoprim
2000 Oxazolidinones
2003 Lipopeptides
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approved 29 new antibacterial drugs. Of these 29
agents, 24 were b-lactams, almost two-thirds of
which were cephalosporins. From 1990 through
1999, the FDA approved 22 new antibacterial
drugs with nine of these belonging to the quino-
lone class and eight belonging to the b-lactam
classs.
With the approval of an increasing number of
agents within classes and the lack of new drug
classes, it is perhaps not surprising that develop-
ment of antibacterial agents would reach a
saturation point. In the 1960s, the FDA
approved 2.9 new antibacterial drugs per year,
which decreased to 2.2 drugs per year in the
1990s and 1.6 drugs per year so far since the
year 2000. However, this decline is not unique to
antibacterial drugs and reﬂects an overall
decrease in the number of all new drugs
submitted to the FDA over this time (Fig. 2)
despite an increase in biomedical research
spending (Fig. 3) [5]. This reﬂects the inherent
challenges in discovering and developing new
drugs in any therapeutic class.
THE PRESENT
Today, antimicrobials are the third most proﬁt-
able class of drugs for pharmaceutical compa-
nies, surpassed only by central nervous system
and cardiovascular drugs. The market for anti-
microbials is between $26 bn [6] and $45 bn per
year. However, introducing an individual new
antimicrobial, especially an antibacterial agent, to
the marketplace may not be as proﬁtable as other
therapeutic classes of drugs. The best selling
antibacterial made $2.01 bn in 2003 but a lipid
lowering agent sold by the same company made
$9.23 bn in that same year [7]. A recent study
showed that the top ﬁve disease states, including
heart disease, pulmonary conditions, mental
disorders, cancer and hypertension, accounted
for 31% of the increase in health care expendi-
tures between 1987 and 2000 [8]. It follows that
drugs to treat those conditions may be more
proﬁtable than those used to treat infectious
diseases, which were number 13 on the list,
accounting for 1.35% of the change in health care
costs over that time.
There are several reasons why antibacterials
may be at a competitive disadvantage relative to
other drugs. There is a high level of competition
with drugs already on the market. As shown
above, there are a number of agents within
various classes still available. While resistance is
an emerging problem in a relative sense, the
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majority of infectious diseases in terms of abso-
lute numbers in the USA are still caused by
susceptible pathogens. The impact of in vitro
resistance may be greatest in serious and
life-threatening diseases which, fortunately, are
relatively less common compared with less seri-
ous illnesses in a developed country like the USA.
This is evidenced by the fact that the majority of
antimicrobials are prescribed on an outpatient
basis. For instance, there are an estimated 4 mil-
lion cases of community-acquired pneumonia
yearly in the USA, but 3 million of those are
treated as outpatients [9]. Also, clinicians may not
perceive antimicrobial resistance as a problem,
thereby decreasing the willingness of a drug
sponsor to develop a drug for which there is not
a perceived need. A recent study by the Centers
for Disease Control (CDC) showed that the
majority of clinicians consider antimicrobial resis-
tance to be a national problem, but not one that
they feel they encounter in their institutions or
their own practices [10]. In addition, clinicians see
the appropriate public health need to preserve
older antimicrobial agents through judicious use,
that is, not prescribing antibacterials to patients
who do not have a bacterial infection. These
patients cannot beneﬁt from therapy but still may
experience adverse effects in addition to harbour-
ing and spreading resistant organisms. Experts
often also recommend reserving new agents for
patients who may have disease caused by resis-
tant pathogens, limiting the potential use of a new
drug. Finally, many antimicrobials are prescribed
for treatment durations ranging from a single
dose to 10 days of treatment. This short-term use
limits the potential proﬁtability of antibacterial
drugs compared with other classes of drugs.
One can compare the development of antivirals
with the development of antibacterials to see
these factors at work (Fig. 4). There are far fewer
antiviral drugs already available than antibacte-
rials, so there is less competition. Many antiviral
drugs are for chronic illnesses like AIDS, and are
prescribed long-term for the life of the patient.
There is less of an issue of inappropriate pre-
scribing, at least with some antivirals, such as
anti-HIV drugs, since diagnostic tests can
accurately select patients who require treatment,
and the need for immediate treatment is less in a
chronic illness than in a bacterial disease that may
be rapidly fatal. Consequently, there has been an
increase over time in the number of FDA
approved antiviral drugs since 1980, with 0.4
drugs approved per year in the 1980s, 1.9 drugs
per year in the 1990s and 1.2 drugs per year so far
in this decade.
In addition, changes within the pharmaceutical
industry itself may be contributing to the decrease
in new antimicrobials [11]. In the last several
years, a number of the larger pharmaceutical
ﬁrms have merged to form even larger entities.
According to members of the industry, larger
ﬁrms require larger proﬁts to sustain themselves,
and may be less willing to develop drugs that are
not ‘blockbusters’. As discussed above, the dis-
eases for which there appears to be the greatest
need are also relatively less common, and drugs
to treat these diseases would not usually be
billion-dollar sellers. In addition, while some
claim that only the resources of large companies
can bring a product to market, other members of
the pharmaceutical industry cite the ‘disecono-
mies of scale’ associated with bringing forward
new ideas within a larger management structure
of a bigger company [11].
Some authors have cited ‘increased regulatory
hurdles’ for antimicrobials as one of the reasons
companies have chosen to exit this ﬁeld [12].
However, there are no increased regulatory hur-
dles for antimicrobials, or speciﬁcally antibacteri-
als, compared with other therapeutic classes.
Some have noted that sponsors of antibacterial
drugs must perform several studies if the drug is
to be approved for the treatment or prevention of
a variety of infectious diseases. This is true of all
therapeutic classes. An oncological drug is not
approved for the treatment of ‘cancer’, but for
speciﬁc forms of cancer, such as lung and breast
cancer. Some antimicrobials, such as those
that treat AIDS, treat one disease syndrome
caused by one pathogen, but these are not
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‘pathogen-speciﬁc’ indications. When a virus can
cause a variety of diseases, such as cytomegalo-
virus, the drug is approved for treatment of that
speciﬁc disease, such as retinitis. It is clear that
some drugs that may be effective in treating a
disease at one body site may not be effective in
treating diseases at another body site; therefore
the need for separate studies is scientiﬁcally
logical. A drug that may be effective in treating
a urinary tract infection or pneumonia may not
necessarily be effective in treating acute bacterial
meningitis.
Other authors have also noted the difﬁculties in
showing similarity of a new antimicrobial to a
highly effective drug that is already on the market
[13]. This challenge is not a ‘regulatory hurdle’ but
a matter of good science and appropriate clinical
trial design and interpretation [14]. The sample
size required to show similar efﬁcacy of a new
drug to an already approved agent is usually
larger than that required to demonstrate superior-
ity of the new drug to other therapies. Authors
have debated the issue of how much worse a new
agent may be compared with the control drug and
still claim ‘similar’ efﬁcacy to the control. What is
clear is that this ‘noninferiority margin’ cannot
be greater than the beneﬁt of the control drug
relative to placebo or to no treatment. For instance,
it is not logical to design a trial to show that the
newdrug can be asmuch as 10% less effective than
the control drug when placebo-controlled trials
show that the control drug may be superior to
placebo by as little as 4%. This means that the new
drug may not be any more effective than placebo.
Selecting the appropriate margin for noninferi-
ority trials is more difﬁcult when the margin of
beneﬁt of antimicrobials compared with placebo
is not known. This is less of an issue in serious
and life-threatening diseases like acute bacterial
meningitis where the magnitude of the treatment
beneﬁts of antimicrobials is clear and very large.
On the other hand, the magnitude of the treat-
ment beneﬁts of antimicrobials in some largely
self-resolving illnesses like acute bacterial sinus-
itis is not clear and may be small. The sample size
of clinical trials in infectious diseases is not larger
than in other therapeutic areas. In fact, clinical
trials in cardiovascular diseases can reach several
thousand for a single trial, larger than the entire
database of several studies contained in a New
Drug Application (NDA) for an antimicrobial
agent.
As stated above, the decrease in approvals of
new antimicrobials reﬂects an overall trend in
decreasing drug approvals in all therapeutic
classes and a decrease in NDAs to the FDA [5].
Part of the high cost of bringing a new drug to
market, quoted as $800 m dollars, includes the
cost of drugs that fail to make it through the
development phase due to lack of efﬁcacy or
safety. It seems logical that the cost of drug
development could be decreased by more accu-
rate selection of drugs that are likely to achieve
the goals of demonstrating safety and efﬁcacy,
and discontinuing early in development of
drugs that will not prove to be safe and
efﬁcacious.
Despite the challenges in developing new
antimicrobials, there are certain advantages for
drug sponsors in developing antimicrobial agents.
Antimicrobials have had the ﬁrst or second
shortest mean and median clinical development
time compared with other therapeutic classes
since 1982 [15]. Given the availability of preclin-
ical in vitro testing and animal models as a ﬁrst
step in selecting appropriate compounds for
further human clinical trials, antimicrobials have
the highest approval success rates of any thera-
peutic class since 1964 [16].
THE FUTURE
A recent analysis showed that there are ﬁve new
antibacterial drugs in development by large phar-
maceutical companies [17]. This analysis does not
evaluate drugs under development by biotech-
nology ﬁrms. At the present time, it is the
experience at the FDA that more biotechnology
ﬁrms are becoming involved in drug develop-
ment of antimicrobials. This would seem to be the
nature of capitalism; as one group decides to exit
a given area, another group perceives an oppor-
tunity. At recent FDA meetings, members of
biotechnology ﬁrms emphasised that the smaller
markets of serious and life-threatening diseases
are more attractive to smaller ﬁrms who can
survive with smaller proﬁts [1,18]. Some have
questioned whether these ﬁrms will have the
necessary resources to perform clinical trials to
develop new drugs. However, venture capital
ﬁrms have been quoted as stating that the need
for large companies to fund clinical trials may be
an overgeneralisation [6]. Venture capitalists
have noted that short-term treatments for acute
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diseases require shorter trials, and coupled with
the higher approval ratings of antimicrobials, this
may make antimicrobial development an attrac-
tive area for investment.
However, it does appear that for certain serious
and life-threatening diseases, especially those
caused by Gram-negative organisms more com-
monly found in the hospital setting, there are few
drugs under development at the present time.
Part of the issue with decreasing drug develop-
ment is there are few new drugs to bring forward
to develop. Many of the drugs under develop-
ment by biotechnology ﬁrms are products that
were discovered by larger pharmaceutical com-
panies and licensed by biotechnology ﬁrms. As
discussed above, it has been difﬁcult to ﬁnd new
classes of antibacterial drugs. The promise of
genomics in discovering new chemical entities
has remained largely unfulﬁlled to date. It may be
that this ﬁeld will yield greater dividends in the
future. In addition, some larger ﬁrms have dis-
mantled the scientiﬁc infrastructure necessary for
antimicrobial drug discovery. The question of
addressing the need for further discovery efforts,
whether by large pharmaceutical companies or
smaller biotechnology ﬁrms, remains an impor-
tant one.
Federal agencies are aware of the need to
address the challenges related to antimicrobial
resistance and to stimulate antimicrobial drug
development. These agencies have been using
their combined resources to attempt to address
these issues. In 2001, a group of ten agencies
chaired by the CDC, the FDA, and the National
Institutes of Health (NIH) formed the Interagency
Task Force on Antimicrobial Resistance. The Task
Force put forward the Public Health Action Plan
for Combating Antimicrobial Resistance [19],
which includes speciﬁc agenda items addressing
product development for diseases due to antimi-
crobial resistant pathogens.
The FDA has taken a number of steps in the last
three years to address the issue of streamlining
drug development for all drugs, and for anti-
microbials in particular [1,18]. The Agency is
putting forward revised guidelines for clinical
trials of various infectious diseases, as requested
by drug sponsors and by interested organisations.
It is hoped that these guidelines will decrease
uncertainty in the drug development process.
These guidelines include recommendations for
superiority trials in certain self-resolving diseases.
Trials that are designed to show the superiority of
an antimicrobial to analgesics or decongestants in
various upper respiratory tract illnesses can
shrink the sample size necessary from the approx-
imately 1500 patients in previous noninferiority
trials reviewed by the FDA to approximately 400
patients for superiority trials. Given the largely
self-resolving nature of many of these diseases,
prescribing symptomatic therapies to all patients,
and incorporating the administration of antimi-
crobials to patients who are failing to improve by
speciﬁc time points (‘early escape’) should allow
conduct of such trials with minimal risk to
patients. The risk of a drug failing to demonstrate
efﬁcacy relative to placebo in such trials may be
more substantial, but then again, this is exactly
what the trial is supposed to be measuring. The
regulatory standard for approval is demonstra-
tion that the study drug is more effective than
placebo, and it would seem implausible that a
drug would be more effective than an active
control if it is not more effective than a placebo. In
serious and life-threatening diseases, it is cer-
tainly appropriate and necessary to perform trials
that show the similarity of new drugs to already
approved agents. In such cases, the FDA has
stated that there is no one universal noninferiority
margin that is applicable to all diseases [14].
Rather, the FDA has afforded drug sponsors the
opportunity to present scientiﬁc data on the
margin of beneﬁt of antimicrobials compared
with placebo or no therapy in the disease under
study in order to select an appropriate margin
and justify the margin they have selected for their
trials.
The FDA has also held several public work-
shops and advisory committee meetings address-
ing issues in reliance upon data from trials in one
disease to lessen the number of trials necessary
for approval in another disease [1,14,18]. The
regulatory basis for approval is ‘adequate and
well-controlled trials’. This has been interpreted
to mean more than one trial in a given disease, in
order to conﬁrm the results seen in a single trial.
However, current regulations allow the approval
of a drug for a given disease based on the results
of a single study plus conﬁrmatory evidence. At a
recent advisory committee in March 2003, the
FDA discussed a plan in which drug sponsors
could perform two trials in a disease of sufﬁcient
severity, such as hospital-acquired or community-
acquired pneumonia, to garner an approval [20].
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Sponsors then could obtain subsequent approvals
for other diseases with a single well-performed
trial in other diseases. At the present time,
regulations do not allow for approval of a drug
for a disease without at least a single clinical
study in that disease. There are exceptions for the
rare circumstance where the disease is impossible
to study or cannot be studied ethically. In such a
case, as with inhalational anthrax, drugs may be
approved according to data from animal studies
alone. It seems inconsistent to claim that diseases
due to resistant pathogens are an increasing
problem and then state that they cannot be
studied, so this ‘animal rule’ does not seem to
apply to most bacterial diseases due to resistant
pathogens.
On the other hand, to perform studies that
include only patients with diseases caused by
resistant pathogens can be challenging. As stated
above, most disease is still caused by susceptible
pathogens. Current diagnostic tests usually do
not differentiate patients with disease due to
resistant and susceptible bacterial pathogens
prior to enrolment. Therefore, the FDA has
approved drugs for diseases due to resistant
pathogens by evaluating the efﬁcacy of drugs for
resistant pathogens within a given clinical trial
for a particular disease [18]. For instance, the
FDA has approved several drugs for community-
acquired pneumonia (CAP) due to multi-
drug-resistant Streptococcus pneumoniae. These
approvals were based on an examination of [1]:
the efﬁcacy of the drug in the trials in CAP as a
whole (due to all pathogens as well as those in
whom a pathogen is not isolated) [2], evaluating
the efﬁcacy of the drug in CAP due to susceptible
strains of S. pneumoniae, and [3] evaluating the
efﬁcacy of the drug in CAP caused by resistant
strains. Given the differences in patient popula-
tions and host factors between those who have
disease due to susceptible pathogens and those
with resistant pathogens, it remains important to
examine some amount of clinical information
from patients with disease due to resistant
pathogens. Similar in vitro activity does not
always translate into similar in vivo efﬁcacy. If
the efﬁcacy of the drug is similar in the various
groups noted above, and there is supportive data
from in vitro studies showing similar MICs of the
drug for susceptible and resistant pathogens, as
well as supportive data from animal studies, the
drug can be approved for disease due to resistant
pathogens. Some drugs have been approved in
this manner with as few as 14 isolates from
patients with disease due to resistant pathogens.
This obviates the need for drug sponsors to
perform separate trials for disease due to resis-
tant pathogens. However, it does require that
sponsors make an effort to enrol patients from
sites where resistant pathogens are more com-
mon so that they have a sufﬁcient likelihood of
enrolling patients with disease caused by these
organisms. It is important to note that this
analysis of efﬁcacy in disease due to resistant
pathogens is not comparing the efﬁcacy of the
new drug to the control drug, nor does it allow a
claim of superiority of a new drug over the
control based on a subgroup analysis. It is merely
conﬁrming similar efﬁcacy of the study drug
across various populations with disease caused
by different pathogens. Drug sponsors may
garner an approval for a drug for disease due
to susceptible pathogens and then submit data
related to disease due to resistant pathogens after
approval. In this way, they may garner an
approval for disease due to resistant pathogens
at a later time without slowing the drug approval
process.
The use of pharmacokinetic and pharmaco-
dynamic (PK-PD) information is also important in
the drug development process. In April 2004, the
FDA cosponsored a workshop with the Infectious
Diseases Society of America (IDSA) and the
International Society of Anti-Infective Pharmacol-
ogy (ISAP) where participants discussed these
issues [18]. While PK-PD information is not a
substitute for data from clinical trials, it can help
in appropriate dose selection. Failure to select the
appropriate dose can result in the failure to
demonstrate efﬁcacy of a new drug and create
the need to perform further clinical trials, with the
resulting increased expense. At the meeting,
participants discussed the tendency for drug
sponsors to skip the Phase II trials that are often
necessary in selecting the appropriate dose, in
order to speed the drug development process. It is
not clear whether this need for speed in the long
run is resulting in longer development times for
new drugs if sponsors proceed to larger, more
expensive Phase III clinical trials without know-
ing the proper dose of antimicrobial to use in the
trial. Phase II trials may be a wise investment in
the long run if they prevent the failure of larger,
more expensive Phase III trials.
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Also during the April workshop, participants
discussed the use of surrogate endpoints for
demonstrating the efﬁcacy of antimicrobials in
clinical trials [18]. These surrogate endpoints are
often microbiological measurements of the pres-
ence or absence of the causative pathogen at
some time after the initiation of therapy. The
current regulations allow the FDA to approve a
drug based on surrogate endpoints that have
already been validated to demonstrate clinical
beneﬁt to patients. Clinical beneﬁt means
improvements in how the patient feels, func-
tions or survives. If the surrogate endpoint has
not been validated, the FDA can grant an
‘accelerated approval’ if the disease under study
is a serious and life-threatening disease and the
surrogate is reasonably likely to predict a
clinical beneﬁt. Drug sponsors then must still
complete trials that show that the surrogate
indeed translates into a clinical beneﬁt for
patients. It has become clear that surrogates
are most useful in chronic diseases. For short-
term illnesses, it is often just as easy, if not
easier, to measure clinical outcomes as it is to
measure the surrogate endpoint. In short-term
diseases, conﬁrming the surrogate would re-
quire initiation of further trials, rather than
continuing to follow patients as done with
chronic diseases.
In March 2004, the FDA put forward an
initiative called the ‘Critical Path’ to drug devel-
opment [5]. The focus of this initiative is on
developing better tools to measure the safety and
efﬁcacy of drugs. These tools may be helpful in
selecting drugs that are more likely to succeed in
demonstrating safety and efﬁcacy in clinical trials.
In addition, better tools can eliminate drugs that
are likely to fail early in the development process,
thus decreasing the costs of these failed drugs that
contribute so much at the present time to the
overall costs of drug development. Tools such as
better diagnostic testing could increase the efﬁ-
ciency of clinical trials for infectious diseases. For
many infectious diseases, it is quite difﬁcult to
differentiate bacterial vs. viral disease. The inclu-
sion of large numbers of patients with viral
disease may dilute the treatment effects of anti-
bacterial drugs. Also, drug sponsors may require
a greater number of patients to enrol sufﬁcient
numbers who truly have bacterial disease. In an
FDA review of clinical trials of acute bacterial
sinusitis, as few as 36% of enrolled patients
actually had bacterial disease when deﬁned by
sinus puncture [21]. In addition, new tools for
measuring clinical outcomes in patients, such as
patient reported outcome scales (PROs), may be
useful in more accurate measurements of clinical
endpoints. FDA guidance on developing such
tools is forthcoming.
CONCLUSIONS
There is clearly a need for new antimicrobials to
combat disease due to resistant pathogens in
serious and life-threatening diseases. Federal
agencies are attempting to do their part in
addressing this need. However, streamlining the
regulatory process will not be useful unless there
are new drugs to put forward on the develop-
ment pathway. This will take an increased effort
in the area of drug discovery, which is beyond the
scope of a regulatory agency. While the FDA is
attempting to streamline the drug development
process, these changes cannot turn a $2 bn drug
into a $9 bn drug. To stimulate drug develop-
ment appears to require economic incentives for
drug sponsors that can only be accomplished by
changes in legislation. Such incentives should
attempt to channel resources towards discovery
and development for those diseases where there
is the greatest need, such as serious infections in
hospitalised patients. The FDA has put forward
several suggestions for streamlining clinical trial
design, allowing smaller sample sizes for indi-
vidual clinical trials, as well as for overall drug
development programmes, while maintaining the
standards that clinicians and patients expect and
deserve. ‘Creative’ clinical trial design does not
imply lower standards and any changes put
forward by the FDA must be within the bounds
of current regulations. The economic needs of the
pharmaceutical industry still must be balanced
against the imperative to protect and advance
public health. Improved clinical trial design
requires the use of better tools in the drug
development process to evaluate efﬁcacy and
safety. It is not the role of the FDA to develop the
tools necessary to move drugs forward, but the
Agency’s breadth of experience in evaluating
both successful and unsuccessful drug develop-
ment programmes can help to guide researchers
in the development of such tools. While there
remain signiﬁcant challenges in the discovery and
development of new antimicrobials, there are still
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advantages for those willing to continue to
advance the science and public health in this
ﬁeld.
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